Writing

Conall Arora

Frameworks and opinions on how IVD trials actually run. Bio

On the record

17 pieces.

  1. FRAMEWORK · Jun 2026 · 12 MIN

    An assay validation scientist runs our trials.

    Structure the CRO so the person who lives in specificity and traceability owns trial execution — not a handoff to generalists.

  2. FRAMEWORK · Jun 2026 · 11 MIN

    Right-size the validation study.

    The conservative protocol that protects the filing can suffocate enrollment — scoping pre-pivotal work for evidence without theatrical burden.

  3. FRAMEWORK · Jun 2026 · 10 MIN

    Qualified site is not the same as a high-enrolling site.

    Most CROs select on regulatory qualification; the signal that predicts enrollment is performance in the field, not paperwork.

  4. FRAMEWORK · Jun 2026 · 12 MIN

    Map the values, then chase them.

    Value-bucket IVD recruitment: map the analytical-range distribution to populations, recruit by segment, and recalibrate weekly with the physicians who see the patients.

  5. FRAMEWORK · Jun 2026 · 7 MIN

    Patient centricity is a buzzword, not a blueprint.

    Patient experience is rarely the bottleneck in IVD trials; standard-of-care-aligned design beats patient-theater checklists.

  6. OPINION · Jun 2026 · 6 MIN

    The over-engineered protocol problem.

    Pre-pivotal validation protocols often recruit themselves into failure — complexity buys paperwork, not subjects.

  7. OPINION · Jun 2026 · 10 MIN

    What if I told you the secret to happiness was hard work you're good at?

    Eighty thousand working hours — the culture treats them as debt against your real life; the alternative is craft you would pay to keep doing.

  8. OPINION · Jun 2026 · 6 MIN

    AI is the car. The driver is everything.

    AI in clinical operations does not produce outcomes — drivers do; people and judgment remain the bottleneck.

  9. OPINION · Jun 2026 · 8 MIN

    The best sites don't have time for you. Cherish the ones that make time, and use it wisely.

    A PI who has all afternoon for your diligence call is not a PI with a busy practice — the friction-rich signal is the one worth designing around.

  10. FRAMEWORK · Jun 2026 · 13 MIN

    The enrollment forecast is the only thing that matters.

    Daily resolution, per-site positive-rate calibration, milestones on the calendar — updated weekly so enrollment reality stays ahead of the spreadsheet.

  11. FRAMEWORK · Jun 2026 · 10 MIN

    The best protocol is one page.

    Compress ruthlessly, leave room for biological variance, and write for who actually runs the study — not the filing cabinet.

  12. FRAMEWORK · Jun 2026 · 13 MIN

    Good site qualification unravels the physician-patient relationship.

    Five principles: the physician–patient relationship is the unit of analysis — and the friction that erodes it is the qualification work most CROs skip.

  13. FRAMEWORK · Jun 2026 · 10 MIN

    The sample spec sheet, and why simplicity is a feature.

    One document, six tables, and roughly 25 fields — scope alignment that auto-builds the SOW because simplicity is a feature.

  14. FRAMEWORK · Jun 2026 · 10 MIN

    Give clients what they need.

    Sponsor partnership as guidance — the CRO is neither order-taker nor know-it-all, but the operator who shows the path.

  15. FRAMEWORK · May 2026 · 11 MIN

    The case report form is a work of art.

    Four principles for IVD CRF design — the case report form is the most-used UX surface on a clinical trial. Treat it like one.

  16. FRAMEWORK · Updated Apr 2026 · 11 MIN

    Trial design framework: put physicians first.

    IVD trials fail to enroll when they ask sites to do something other than care for patients. Across 300+ IVD studies since 2011, the protocols that recruit on schedule share one property: study activities fit inside the patient visit that was going to happen anyway. We call this standard-of-care alignment. Patient centricity is the buzzword; physician fit is the mechanism.

  17. FRAMEWORK · Apr 2026 · 12 MIN

    Healthy collection is the most misunderstood cohort.

    Healthy is not the hardest cohort — it is the most miscategorized. Defined positively and run as a reference-range study, it becomes one of the cleanest deliverables a CRO can produce.

Conall Arora is CEO, RDI.

CEO of RDI. Acquired the company in 2017 and has led it since — the team, the systems, and the physician network that let customers of every size benefit from a specialist CRO.